

Serial No.: 10/728,491

Attorney Docket No.: 11520.0338

24. (Original) The method of claim 21, wherein the administration of the composition is combined with a treatment selected from the group consisting of surgery, radiation, chemotherapy and immunotherapy.

25. (Original) The method of claim 21, wherein the composition is administered via a route selected from the group consisting of intratumoral, intravenous, intraperitoneal, intramuscular, intranasal, oral, topical and rectal.

26. (Original) A method for detecting the overexpression of the RI<sub>a</sub>/PKA gene in a test sample comprising the steps of:

- a) isolating nucleic acids from the test sample and a control sample;
- b) contacting the nucleic acids from the test sample and the control sample with the oligoribonucleotide of claim 1 or a complement thereof; and
- c) comparing hybridization of the nucleic acids from the test and the control sample to the oligoribonucleotide of claim 1 or the complement thereof,  
wherein an increase in the hybridization in the test sample is indicative of the overexpression of the RI<sub>a</sub>/PKA gene in the test sample.

27. (Original) The method of claim 26, wherein the nucleic acids are mRNA.

28. (Original) The method of claim 26, wherein the nucleic acids are reverse transcribed from mRNA.

*③ x 29*  
29. (Original) The method of claim 26, wherein the oligoribonucleotide is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:10, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19 and SEQ ID NO:22.

*30 x 30*  
30. (Original) The method of claim 29, wherein the oligonucleotide has a sequence of SEQ ID NO:1.

Serial No.: 10/728,491

Attorney Docket No.: 11520.0338

- 83  
2/9/2004*
- 31 32. (Original) An oligoribonucleotide of from 18 to 30 nucleotides comprising:  
a contiguous sequence of SEQ ID NO:20 or a sequence which has one-base  
mismatch with SEQ ID NO:20,  
wherein the ribose residue of at least one nucleotide is protected at the 2'-O- position by  
2, 4-dinitrophenyl (DNP) and wherein the oligoribonucleotide is capable of down-regulating the  
expression of the RL<sub>α</sub> subunit of protein kinase A.
- 32 33. (Original) The oligoribonucleotide of claim 32, which has a sequence of SEQ ID NO:20.
- 33 34. (Original) A composition comprising the oligoribonucleotide of claim 32.